Postmethionine-load homocysteine determination for the diagnosis hyperhomocysteinaemia and efficacy of homocysteine lowering treatment regimens

Abstract

Substantial epidemiological evidence supports the vision that moderate hyperhomocysteinaemia is a graded and independent cardiovascular risk factor. The additional value of the methionine loading test for the assessment of hyperhomocysteinaemiacontinues to be disputed.

This overview presents the historical background for the rationale of the methionine loading test and describes determinants and variability of the postmethionine-load homocysteine concentration. The association of postmethionine-load homocysteine concentrations and the risk of cardiovascular events is discussed. Furthermore, the results of homocysteine lowering treatment on postmethionine-load homocysteine are given.

Up to 50% of subjects with hyperhomocysteinaemia can only be detected after performing a methionine loading test; these subjects have a normal fasting homocysteine. Both fasting and postmethionine-load homocysteine concentrations are influenced by serum folate and creatinine concentrations and by the methylenetetrahydrofolate reductase genotype, and may be subject to a wide intra-individual variability (20%).

Cross-sectional studies suggest that cardiovascular risk may increase gradually from post-methionine-load homocysteine concentrations above 38 m mol/l. Supplementation with folic acid 0.5 mg daily adequately reduces postmethionine-load homocysteine; addition of pyridoxine appears to have no further homocysteine lowering effect.

Prospective studies supporting the clinical significance of the methionine loading test for individual patient counselling are lacking; it seems, therefore, prudent to restrict this test for research purposes.

Keywords

folic acid homocysteine hyperhomocysteinaemia methionine loading test pyridoxine

References

McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-128.

Mudd SH , Levy HL , Skovby F. Disorders of transsulfuration. In: Scriver CR , Beaudet AL , Sly WS , Valle D (eds). The metabolic and molecular bases of inherited disease, 7th edition. New York: McGraw-Hill, 1995: 1279-1327.

Fowler B , Sardharwalla IB , Robins AJ. The detection of heterozygotes for homocystinuria by oral loading with l-methionine. Biochem J 1971; 122: 23P-24P.

Boers GHJ , Smals AGH , Trijbels FJM et al. Heterozygosity for homo-cystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709-715.

Brattström LE , Israelsson B , Hultberg B. Plasma homocysteine and methionine tolerance in early-onset vascular disease. Haemostasis 1989; 19: S35-S44.

Clarke R , Daly L , Robinson K et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-1155.

Kraus JP , Le K , Swaroop M et al. Human cystathionine-synthase cDNA: sequence, alternative splicing and expression in cultured cells. Hum Mol Genet 1993; 2: 1633-1638.

Kozich V , Kraus E , de Franchis R et al. Hyperhomocysteinemia in premature arterial disease: examination of cystathionine -synthase alleles at the molecular level. Hum Mol Genet 1995; 4: 623-629.

Kluijtmans LAJ , van den Heuvel LPWJ , Boers GHJ et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.

10.

Den Heijer M , Bos GMJ , Brouwer IA , Gerrits WBJ , Blom HJ. Variability of the methionine loading test: no effect of a low protein diet. Ann Clin Biochem 1996; 33: 551-554.

11.

Bostom AG , Jacques PF , Nadeau MR , Williams RR , Ellison RC , Selhub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. Atherosclerosis 1995; 116: 147-151.

12.

Fermo I , Vigano’ D’Angelo S , Paroni R , Mazzola G , Calori G , D’Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995; 123: 747-753.

13.

Van der Griend R , Haas FJLM , Duran M , Biesma DH , Meuwissen OJATh , Banga JD. Methionine loading test is necessary for detection of hyperhomocysteinemia. J Lab Clin Med 1998; 132: 67-72.

14.

Graham IM , Daly LE , Refsum HM et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997; 277: 1775-1781.

15.

Verhoef P , Kok FJ , Kluijtmans LAJ et al. The 677C T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary artery disease. Atherosclerosis 1997; 132: 105-113.

16.

Den Heijer M, Bos GMJ, van der Boor RPGM et al. Mutated methylenetetrahydrofolate reductase and other determinants of plasma homo-cysteine before and after methionine loading in a general Dutch population. In: den Heijer M (ed). Hyperhomocysteinemia and venous thrombosis [Dissertation]. Leiden: Leiden University, 1997: 37-55.

17.

De Jong SC , Stehouwer CDA , van den Berg M et al. Determinants of fasting and post-methionine homocysteine levels in families predis-posed to hyperhomocysteinemia and premature vascular disease. Arterioscler Thromb Vasc Biol 1999; 19: 1316-1324.

18.

Silberberg J , Crooks R , Fryer J et al. Gender differences and other determinants of the rise in plasma homocysteine after l-methionine loading. Atherosclerosis 1997; 133: 105-110.

19.

Ubbink JB , van der Merwe A , Delport R et al. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 1996; 98: 177-184.

20.

Stampfer MJ , Malinow MR , Willett WC et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881.

21.

Nygard O , Nordrehaug JE , Refsum H , Ueland PM , Farstad M , Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-236.

22.

Den Heijer M , Blom HJ , Gerrits WBJ et al.

Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis?

Lancet 1995; 345: 882-885.

23.

Van den Berg M , de Jong SC , Devillé W et al. Variability of fasting and post-methionineplasma homocysteine levels in normo- and hyper- homocysteinaemic individuals. Neth J Med 1999; 55: 29-38.

24.

Andersson A , Brattström L , Israelsson B , Isaksson A , Hamfelt A , Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest 1992; 22: 79-87.

25.

Ueland PM , Refsum H , Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis RB Jr (ed). Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York: Marcel Dekker, 1992: 183-236.

26.

Van den Berg M , Stehouwer CDA , Bierdrager E , Rauwerda JA. Plasma homocysteine and severity of atherosclerosis in young patients with lower extremity atherosclerotic disease. Arterioscler Thromb Vasc Biol 1996; 16: 165-171.

27.

Cattaneo M , Martinelli I , Mannucci PM. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis [Letter]. N Engl J Med 1996; 335: 974-975.

28.

Verhoef P , Kok FJ , Kruyssen DACM et al. Plasma total homocysteine, B-vitamins and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 989-995.

29.

Homocysteine Lowering Trialists’ Collaboration . Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Br Med J 1998; 316: 894-898.

30.

Ubbink JB , Vermaak WJH , van der Merwe A , Becker PJ , Delport R , Potgieter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994; 124: 1927-1933.

31.

Franken DG , Boers GHJ , Blom HJ , Trijbels JMF. Effect of various regimens of vitamin B6 and folic acid on mild hyperhomocysteinaemia in vascular patients. J Inherit Metab Dis 1994; 17: 159-162.

32.

Van der Griend R , Biesma DH , Haas FJLM et al. The effect of different treatment regimens in reducing fasting and postmethionine-load homocysteine concentrations. J Intern Med 2000; 248: 223-229.

33.

Van den Berg M , Franken DG , Boers GHJ et al. Combined vitamin B6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. J Vasc Surg 1994; 20: 933-940.

34.

De Jong SC , Stehouwer CDA , van den Berg M , Geurts TW , Bouter LM , Rauwerda JA. Normohomocysteinemia and vitamin-treated hyperhomocysteinemia are associated with similar risks of cardiovascular events in patients with premature perpheral arterial occlusive disease. A prospective cohort study. J Intern Med 1999; 246: 87-96.

35.

Van der Griend R , Haas FJLM , Biesma DH , Duran M , Meuwissen OJATh , Banga JD. Combination of low-dose folic acid and pyridoxine for treatment of hyperhomocysteinaemia in patients with premature arterial disease and their relatives. Atherosclerosis 1999; 143: 177-183.

36.

Van Guldener C , Janssen MJFM , de Meer K , Donker AJM , Stehouwer CDA. Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine levels in chronic dialysis patients. J Intern Med 1999; 245: 175-183.

37.

Bostom AG , Gohh RY , Bealieu AJ et al. Treatment of hyperhomocysteinemia in renal transplant recipients. Ann Intern Med 1997; 127: 1089-1092.

38.

Clarke R , Collins R. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk 1998; 5: 249-255.

39.

Grundy SM , Bazzarre T , Cleeman J et al. Prevention Conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention. Circulation 2000; 101: e3-e11.